特立帕肽注射液人體等效性研究現狀分析及相關考慮( 四 )


五、參考文獻
[1]《中國骨質疏松癥流行病學調查報告2018.》
[2]特立帕肽注射液(復泰奧?)中文說明書.
[3]特立帕肽注射液(フォルテオ?皮下注キット600μg)日本IF文件.
[4]特立帕肽注射液生物類似藥臨床試驗設計指導原則》.
[5]livogiva-epar-public-assessment-report_en.EMA
[6]FORTEO(teriparatideinjection),forsubcutaneoususe.FDAlable.
[7]movymia-epar-public-assessment-report_en
[8]sondelbay-epar-public-assessment-report_en.EMA
[9]Farías,J.,Keller,G.A.,Papouchado,M.,VillaEtchegoyen,M.C.,Criscuolo,M.E.,Diez,R.A.,&DiGirolamo,G.(2016).Relativebioavailabilitybetweentwoteriparatideformulationsinhealthyvolunteers.Internationaljournalofclinicalpharmacologyandtherapeutics,54(8),649–656.
[10]Takács,I.,Jókai,E.,Kováts,D.E.,&Aradi,I.(2019).Thefirstbiosimilarapprovedforthetreatmentofosteoporosis:resultsofacomparativepharmacokinetic/pharmacodynamicstudy.Osteoporosisinternational:ajournalestablishedasresultofcooperationbetweentheEuropeanFoundationforOsteoporosisandtheNationalOsteoporosisFoundationoftheUSA,30(3),675–683.
[11]特立帕肽注射液(CXSS2100011)申請上市技術審評報告.返回搜狐 , 查看更多
責任編輯: